ESG risk score 23.79
Environmental score -
Social score -
Governance score -
ESG risk category Medium
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Halozyme Therapeutics Inc.
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol HALO:xnas
Currency USD
NASDAQ
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -6.27%
1 year 5.54%
3 years 64.57%
Data provided by 
Key stats
Price/earnings (LTM) 25.32
Dividend yield (LTM) -
EPS (LTM) 2.49
Volatility (30 days) 31.27%
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Sector Healthcare
Industry -
Market cap 8bn
Data provided by /
/ Frequently asked questions
To buy Halozyme Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Halozyme Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Halozyme Therapeutics Inc. is HALO:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Halozyme Therapeutics Inc. has its primary listing on NASDAQ. You can trade Halozyme Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Halozyme Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Halozyme Therapeutics Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Halozyme Therapeutics Inc. or others.